Antares Pharma, Inc. (NASDAQ: ATRS) today announced the election of Robert P. Roche Jr. to the Company’s Board of Directors. Mr. Roche has served as principal of Robert Roche Associates LLC, a consulting firm providing guidance to the pharmaceutical and healthcare industries since February 2010. From January 1995 through February of 2010, Mr. Roche led commercial operations at Cephalon, Inc., a global biopharmaceutical company. Prior to his retirement from Cephalon, Mr. Roche held the position of Executive Vice President, Worldwide Pharmaceutical Operations, in which capacity he oversaw several successful new product launches. Leonard S. Jacob, M.D., Ph.D., Chairman of the Board of Antares Pharma, stated, “The addition of Bob Roche to our Board is welcomed and timely. His background and success in commercial operations and product launches will serve to complement the experienced sales and marketing team that Antares has assembled. Subject to FDA approval, the Company plans to launch OTREXUP™ for the treatment of rheumatoid arthritis early next year.” “I am excited to be joining the Board of Antares Pharma at this point in the Company’s growth,” said Robert P. Roche Jr. “The Company has developed a comprehensive commercialization plan for OTREXUP™ which I am confident will result in a well-coordinated launch early next year. The launch plan will also serve as a template for other drug-device combination products in their pipeline, such as QS T for Testosterone Replacement Therapy,” added Mr. Roche. Mr. Roche was elected unanimously by the Company’s Board of Directors at the recommendation of the Nomination and Governance Committee. Before joining Cephalon, Mr. Roche served as Director and Vice President, Worldwide Strategic Product Development for SmithKline Beecham’s central nervous system and gastrointestinal products business. Prior to that, he held senior marketing positions in Canada and Spain and had product planning responsibilities for SmithKline in Latin America. Mr. Roche began his pharmaceutical career in 1982 with SmithKline & French as a U.S. Pharmaceutical sales representative. He is a graduate of Colgate University and earned an MBA from the Wharton School at the University of Pennsylvania.